Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study

Abstract

Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis. Materials and methods: a prospective cohort clinical trial involved 50 patients with HCV (including 30 patients with compensated cirrhosis of the liver, class A in Child-Pugh), caused by genotype 1b. All patients received asunaprevir in a dose of 100 mg twice a day in combination with daclatasvir 60 mg once a day. Th e duration of the treatment course was 24 weeks. Th e effi cacy criterion was the undetectable level of HCV RNA 24 weeks aft er the end of antiviral therapy (SVR24). Results: at the end of the 4th week of treatment, aviremia was achieved in 92% of patients. Th e incidence of SVR24 in previously untreated patients was 90%, in the group of patients who did not respond to previous therapy with pegylated interferon-interferon with ribavirin- 86.9%. Conclusion: Th e combination of asunaprevir with daclatasvir is highly eff ective and provides a sustained virologic response in 86-90% of cases. A low incidence of adverse events (8%) demonstrates a favorable safety profi le of this treatment regimen.

Keywords

• chronic hepatitis c
• asunaprevir
• daclatasvir